Thermo Fisher Scientific Pembrolizumab Monoclonal Antibody (90G12), MonoRab

Applications and Tested Dilution

Product Specifications

Product Specific Information

Lyophilized antibody should be reconstituted with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.

Pembrolizumab (Keytruda) is a humanized monoclonal antibody approved by the U.S. FDA for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, leading to activation of T-cell-mediated immune responses against tumor cells.

GenScript MonoRab™ Anti-Pembrolizumab Antibody (90G12), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Pembrolizumab.

Target Information

Pembrolizumab (Keytruda) is a humanized monoclonal antibody that binds PD-1, blocking PD-L1 interaction and restoring T-cell activity against tumor cells. It is FDA-approved for use in patients with unresectable or metastatic melanoma.

For Research Use Only.
Not for use in diagnostic procedures.
Not for resale without express authorization.